Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TulmiSTAR-02 in metastatic hormone-sensitive prostate cancer
2025-521873-15-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, open-label trial of tulmimetostat in prostate cancer (PCa) (4 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 1 more. Planned start Feb 2026; status: authorised.
02
Drugs
tulmimetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2025-521873-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521873-15-00.